Gly-β-MCA 

Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders^[1].

FXR^[1].

Gly-β-MCA, a bile acid, is a potent, sable and intestine-selective and farnesoid X receptor (FXR) inhibitor^[1].
Gly-β-MCA (Gly-MCA, ) is resistant to hydrolysis by BSH^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Gly-β-MCA (Gly-MCA, p.o. 10 and 50 mg/kg) prevents and treats diet-induced and genetic obesity, along with insulin resistance and hepatic steatosis without systemic, hepatic or intestinal toxicities in mice^[1].
Gly-MCA does not increase faecal LCN-2 levels, indicating that Gly-MCA does not induce intestinal inflammation^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

465.62

Solid

C₂₆H₄₃NO₆

66225-78-3

C[[email protected]@H]([[email protected]@]1([H])CC[[email protected]@]2([H])[[email protected]@]3([H])[[email protected]]([[email protected]]4(CC[[email protected]@H](O)C[[email protected]]4[[email protected]](O)[[email protected]@H]3O)C)([H])CC[[email protected]]12C)CCC(NCC(O)=O)=O

Room temperature in continental US; may vary elsewhere.

• [1]. Jiang C, et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Commun. 2015 Dec 15;6:10166.  [Content Brief]